Publicly-Traded Addiction Treatment Co. Signs Exclusive Licensing Agreement With Alar Pharmaceuticals
Portfolio Pulse from Nina Zdinjak
Addiction treatment company Indivior PLC (NASDAQ:INDV) has signed an exclusive licensing agreement with Alar Pharmaceuticals. Indivior will pay $10 million to secure exclusive global rights to develop, produce and commercialize Alar's portfolio of long-acting injectable formulations, including its lead candidate, ALA-1000. This is in addition to an initial $5 million option payment made by Indivior to Alar in Q1. Alar is entitled to potential milestone payments if various developmental, regulatory, and commercial goals are achieved.
October 13, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Indivior's exclusive licensing agreement with Alar Pharmaceuticals could potentially broaden its product portfolio and address unmet patient needs in the treatment of opioid use disorder.
The licensing agreement allows Indivior to develop, produce and commercialize Alar's portfolio of long-acting injectable formulations. This could potentially expand Indivior's product portfolio and address unmet patient needs in the treatment of opioid use disorder, which could positively impact the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100